Oceans Bio (332190) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Oceans Bio is dated 2025-01-14; the most recent is 2026-03-27. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-03-27 | BUY | 유상신주취득 | 캡스톤파트너스 Capstone Partners | - | 228.6K | ₩1,489 | +24.2% | ₩340M ($236K) |
| 2025-03-31 | SELL | 임원퇴임 | 강귀염 Gangwiitis | Managing Director | -37.5K | ₩2,690 | -0.4% | ₩101M ($70K) |
| 2025-01-14 | BUY | 신규상장 | 이현웅 Hyeonwoong Lee | CEO | 1.2M | ₩8,930 | -69.8% | ₩10.4B ($7.2M) |
| 2025-01-14 | BUY | 신규상장 | 강귀염 Gangwiitis | Managing Director | 37.5K | ₩8,930 | -69.8% | ₩335M ($233K) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Oceans Bio. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.